Compare Natera Inc. Common Stock (NTRA) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Ryanair Holdings plc — how do they compare? Natera Inc. Common Stock trades at $394.16 (market cap $57.03B), while Ryanair Holdings plc trades at $52.01 (market cap $26.41B). The key difference: Natera Inc. Common Stock is far larger — about 2.2× Ryanair Holdings plc's market cap, and Ryanair Holdings plc pays a 1.69% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Ryanair Holdings plc for 72 Days on average.
| NTRA | RYAAY | |
|---|---|---|
Market Cap | $57.03B | $26.41B |
Volume | 1,131,157 | 2,266,391 |
Sector | Health | Industrials |
52-Week High | $425.64 | $73.82 |
52-Week Low | $179.42 | $51.33 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $56.18B | $23.47B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
RYAAY trades at $51.33, down 3.15% amid bearish technical signals despite strong fundamentals. The stock shows robust profitability with 12.13% net margins and attractive valuation at 13.23 P/E. Recent earnings performance has been mixed with Q1 2026 beating expectations but Q2 2026 missing. Technical indicators signal bearish momentum with oversold RSI conditions, while analyst consensus remains positive with 64.71% buy ratings.
The outlook balances strong operational performance against near-term headwinds including fuel cost volatility and Boeing MAX 10 certification delays. Revenue growth trajectory and market share gains support long-term potential, though elevated oil prices and competitive pressures present significant risks. Current valuation levels offer entry opportunity for patient investors despite technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
